【大摩:中国生物制药(01177.HK)收购礼新医药作价合理 予目标价4.9港元】智通财经APP获悉,摩根士丹利发布研报

智通财经
16 Jul
【大摩:中国生物制药(01177.HK)收购礼新医药作价合理 予目标价4.9港元】智通财经APP获悉,摩根士丹利发布研报称,中国生物制药(01177.HK)公布以5.01亿美元收购礼新医药(LaNova)剩余95.09%股权,而早前公司已以1.42亿元人民币获得4.91%股权。该行认为交易定价合理,因LaNova拥有多项后期管线,并已完成2项对外授权协议,这次收购将为中生制药带来多项技术平台,进一步强化其肿瘤管线布局;现予目标价4.9港元及“增持”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10